CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies

SIMPLE SUMMARY: CD123 is overexpressed in multiple hematologic malignancies. Advances in CD123-targeted therapies over the past decade have positioned this molecule as an integral biomarker in current practice. This review provides an overview of CD123 biology and in-depth discussion of clinical lab...

Descripción completa

Detalles Bibliográficos
Autores principales: El Achi, Hanadi, Dupont, Edouard, Paul, Shilpa, Khoury, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690688/
https://www.ncbi.nlm.nih.gov/pubmed/33113953
http://dx.doi.org/10.3390/cancers12113087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690688/
https://www.ncbi.nlm.nih.gov/pubmed/33113953
http://dx.doi.org/10.3390/cancers12113087

Ejemplares similares